[dt_sc_h2 class=””]Overview[/dt_sc_h2][dt_sc_clear /][dt_sc_two_third first][dt_sc_h2 class=””]Welcome to TRIM-edicine[/dt_sc_h2]
TRIM-edicine is an rapid growing, privately held biotechnology company engaged in the development of novel biopharmaceutical products for the treatment of unmet medical needs, including oral healthcare, dermal wounds, ischemia/reperfusion injury, sports medicine and muscular dystrophy. The company is built around a core of novel proteins with remarkable biological properties. These unique proteins target a variety of cellular pathways that are altered in numerous disease states. Learn more about our science and technology. R&D efforts at TRIM-edicine focus on providing proof-of-concept support to validate our technology and facilitate partnerships with various established companies in the biomedical field.
As of 2015 – TRIM-edicine has obtained global patent protection on MG53, including composition and utility applications.
[/dt_sc_one_third]